← Leaderboards
Sunitha Kakarla
Viracyte, Llc
$645,996
Attributed
$1,305,114
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $988.7K · FY2016–18$1M$750K$500K$250K$0
'16
'17
'18
Funding mix
By agency
NIH$988,677 · 1
FDA$316,437 · 1
By mechanism
R44$988,677 · 1
R01$316,437 · 1
Top collaborators
- Adrian Philip Gee1 shared
- John Wilson1 shared
Others in their field
Top investigators on “Adoptive Transfer”
- Carl H. June · University Of Pennsylvania$34,559,203
- David Heimbrook · Leidos Biomedical Research, Inc.$31,285,017
- Stanley R Riddell · Fred Hutchinson Cancer Center$24,395,993
- David Artis · Weill Medical Coll Of Cornell Univ$21,071,488
- James L Riley · University Of Pennsylvania$20,821,861
- Antoni Ribas · University Of California Los Angeles$20,752,587
Research focus
Adoptive TransferAdverse EffectsAllogenicAlternative TherapiesAntiviral AgentsBaseBiologicalBk VirusBloodB-LymphocytesCell BankCell CountCell Culture TechniquesCell LineCellsChildCidofovirClinical InvestigationCollaborationsCollegeCommercializationCommunitiesContractsAccelerometer
Grant awards (3)
Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)$66,574
R01 · FY2018 · FD · contact PI
Path to Commercialization of the first âoff the shelfâ T cell product$988,677
R44 · FY2017 · HL · contact PI
Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)$249,863
R01 · FY2016 · FD · contact PI